MAY 12, 2016 1:30 PM PDT

The benefits and burdens of assaying matched normal tissue when sequencing cancer genomes

Speaker
  • Lead Bioinformatics Scientist, Personalis, Inc.
    Biography
      Elena Helman joined Personalis, Inc. in January 2014 as a Bioinformatics Scientist, Technical Lead where she has been instrumental in leading the development of the cancer DNA products and pipeline. This includes designing and implementing a somatic analysis pipeline for cancer exome and targeted gene panel sequencing, including small variant and copy-number calling, variant annotation and reporting. Elena received her PhD in Bioinformatics and Integrative Genomics from Harvard-MIT Division of Health Sciences and Technology (HST). For her graduate work in Matthew Meyerson's Lab at the Broad Institute and Dana Farber Cancer Institute, she developed a novel tool to identify somatic retrotransposon insertions using whole-genome and whole-exome next-generation sequencing data from hundreds of tumor samples across The Cancer Genome Atlas (TCGA).

    Abstract

    Targeted sequencing assays are increasingly used to identify tumor mutations that guide therapeutic decisions. Interpretation of a cancer variant’s origin and therapeutic impact poses analytical challenges. Recent studies have indicated that jointly analyzing a tumor with its matched normal can accurately discriminate between somatic and inherited mutations. However, procurement of a matched sample is often logistically impractical. In the absence of a matched normal, large databases and analytical techniques are currently used to identify cancer variants in tumor sequencing data. Whether the benefits outweigh the additional burden of sequencing the matched normal for accurate detection of cancer-relevant mutations remains an open question. For NGS-based cancer interpretation to guide clinical decisions in a practical and cost-effective manner, highly optimized tumor-only and tumor/normal analyses must be available with proper attention to germline consent, classification and education.

    Learning Objectives:

    • Understanding the differences in pipelines, filtering, and use of large population databases necessary depending on the availability of a matched normal
    • Consideration of the burden of secondary findings when sequencing a matched normal 
    • Defining your “actionable” set of variants drastically affects analysis results

    Show Resources
    You May Also Like
    MAY 11, 2021 10:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    MAY 11, 2021 10:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
    NOV 16, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 16, 2020 8:00 AM PST
    Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
    NOV 10, 2020 7:00 AM PST
    C.E. CREDITS
    NOV 10, 2020 7:00 AM PST
    DATE: November 10, 2020 TIME: 7:00am PDT, 10:00am EDT Automation can provide tremendous benefits such as increased pipetting precision and accuracy, productivity, and throughput. Numerous wo...
    FEB 24, 2021 10:00 AM PST
    C.E. CREDITS
    FEB 24, 2021 10:00 AM PST
    DATE: February 24, 2021 TIME: 10am PST Automated lab instruments such as liquid handlers and cell sorters are increasingly common in all types of laboratories, driving fast results for labor...
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    DEC 03, 2020 4:30 PM PST
    C.E. CREDITS
    DEC 03, 2020 4:30 PM PST
    This drug development program is designed to create a family of broad-spectrum, pan-coronaviral drugs that respectively inhibit multiple key enzymes required for viral replication. By target...
    MAY 12, 2016 1:30 PM PDT

    The benefits and burdens of assaying matched normal tissue when sequencing cancer genomes


    Specialty

    Antibodies

    Virology

    Immunology

    Dna Sequencing

    Personalized Medicine

    Clinical Diagnostics

    Immunity

    Cancer Diagnostics

    Immunotherapy

    Bioinformatics

    Flow Cytometry

    Immuno-Oncology

    Gene Expression

    Dna

    Big Data

    Geography

    Europe100%

    Registration Source

    Website Visitors100%

    Job Title

    Student100%

    Organization

    Academic Institution100%


    Show Resources
    Loading Comments...
    Show Resources
    Attendees
    • See more